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1

A Growing Tradition of Laboratory Animal Use

Researchers have sought to understand the mechanisms of human health and
disease, for as long as the latter has existed. Serious interest in the structure
and functioning of the human body has been evident at least since the ancient
Greeks. However, the investigations of Greek physicians into human anatomy
and physiology were greatly hampered by social taboos about dissecting human corpses (von Staden, 1989). But non-human animals (hereinafter referred
to as animals), were not so revered or feared. Some dissected their corpses,
while others, such as Alcmaeon of Croton (sixth–fifth century, bce), practiced surgical or other invasive procedures on the living (Court, 2005; Maehle
and Tröhler, 1990), and conducted some of the first animal experiments ever
recorded.
Almost two millennia passed before such social dogmas were seriously questioned. The Renaissance heralded a new era of scientific inquiry, during which
Flemish physician and surgeon Vesalius (1514–1564) began to source human
cadavers for dissection illegally. He discovered that a number of anatomical
structures believed to exist, following animal dissections, were unexpectedly
absent in humans. His highly accurate anatomical descriptions challenged the
authoritative texts of classical authors (O’Malley, 1964).
Throughout the seventeenth century the spirit of scientific inquiry grew and
with it, experimentation on living animals. Some surgical investigations and
demonstrations that predated anesthesia were infamously cruel and caused
widespread social controversy. However, French philosopher, René Descartes
(1596–1650), famously rebutted such critiques, claiming that animals were
merely mindless automata, i.e., “machine-like” (Descartes, 1989); their cries
were of no greater moral consequence than the squeals of a p
 oorly-oiled
machine.
Nevertheless, by the end of the seventeenth century, the question of animal
suffering and the acceptability of such procedures had become an i ncreasingly
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prominent moral and social concern (Maehle and Tröhler, 1990). Jeremy Bentham (1748–1832), famously asked, “The question is not, Can they reason? nor,
Can they talk? but, Can they suffer?” (Bentham, 1823, Chapter 17, footnote).
And his concerns have been echoed by many others since.
By the beginning of the nineteenth century, a revolution had begun within
medicine. Growing awareness of the poor effectiveness of many traditional
therapies led to investigations focused on understanding disease etiology
(causation) and pathogenesis (progression), with the intention of increasing
diagnostic and prognostic accuracy and treatment efficacy. The use of animals
as investigative models increased in the second half of the nineteenth century,
often in highly-invasive research and still predating most forms of anesthesia
or analgesia. Increasing social unease about such research led to widespread
opposition in Europe, and especially Britain, where organizations, such as the
National Anti-Vivisection Society (navs), founded 1875, (navs, 2012) and the
British Union for the Abolition of Vivisection, founded 1898, (now Cruelty Free
International, n.d.), were established to campaign against it. The Cruelty to
Animals Act (1876) entered into force, becoming the first legislation to regulate
animal experiments (Franco, 2013).
In the latter part of the twentieth century, social concerns about animal suffering continued to grow, accompanied by a seemingly inexorable rise in animal
experimentation. Currently, the most accurate evidence-based estimates of
global laboratory animal use describe the year 2005. Approximately 126.9 million non-human vertebrates were used worldwide in that year (Knight, 2008a;
Taylor et al., 2008). Driven by increased development and use of geneticallymodified animals (Ormandy, Schuppli and Weary, 2009), and by large-scale
chemical-testing programs (Knight, 2011), laboratory animal use has steadily
increased in most developed countries, ever since.
The single largest category of research conducted today is fundamental biological research, much of which has no obvious application. The European
Union (EU) is the world’s largest region that publishes comprehensive analyses of its laboratory animal use. At the time of writing, the most recent published figures describe animal use in the 27 Member States of the EU in 2011
(with one state reporting for 2010). Within this period, 46.1% of the 11.5 million
animals were used for this purpose. However, barring 1.6% of animals used for
education and training, most of the remaining 52.3% were used in attempts
to advance public health—for research, development, or toxicity testing; for
quality control of products and devices for human or veterinary medicine and
dentistry; or for disease diagnosis and other purposes (European Commission,
2013). Most of these animals would have been used in attempts to advance human, rather than animal, health.
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Effectiveness of Laboratory Animal Use

Combined, this represents an enormous commitment of animal, scientific,
personnel, and financial resources, ostensibly dedicated primarily to the advancement of human health. But how effective has all this research been?
Advocates of such research have regularly claimed it is essential for preventing, curing, or alleviating human diseases (e.g., Brom, 2002; Festing, 2004);
and further, that the greatest achievements of medicine have only occurred
through the use of animals (e.g., Pawlik, 1998). However, those who champion
such claims frequently have careers dependent on such research. Furthermore, counter-narratives by others contest the contributions or necessity of
such research for the advancement of medical progress (e.g., Greek and Greek,
2002). To support their argument, advocates on either side regularly cite cases
in which animal and human outcomes are similar or different. However, only
small numbers of experiments are normally included in such reviews, and
their selection may be subject to bias. These are known as narrative reviews.
To provide more definitive conclusions, systematic reviews of the human
clinical or toxicological utility of large numbers of animal experiments are
necessary. A systematic review is “a review of a clearly formulated question
that uses systematic and explicit methods to identify, select, and critically appraise relevant research and to collect and analyze data from the studies that
are included in the review. Statistical methods (meta-analysis) may or may not
be used to analyze and summarize the results of the included studies” (Moher
et al., 2009). In recent years, systematic reviews have become widely utilized
to investigate a broad range of clinical and other research questions. Their
aims are to retrieve as much high-quality evidence as possible, relevant to the
research question, and to minimize bias during the selection, analysis, and
reporting of results. Any conclusions reached should, accordingly, be as close
as possible to biological, physical, chemical, or other truths.
A large number of systematic reviews of animal experiments within various
research fields have examined their utility for advancing human healthcare,
and the results have not been good. Of 20 published systematic reviews examining human-clinical utility located during a comprehensive literature search,
animal models demonstrated significant potential to contribute toward clinical interventions in only two cases, one of which was contentious. Included
were experiments approved by ethics committees on the basis of claims that
medical advances were likely to result; highly-cited experiments published
in leading journals; and chimpanzee experiments, utilizing the species most
generally predictive of human outcomes. Seven additional reviews failed to
demonstrate utility in reliably predicting human toxicological outcomes,
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including those associated with the greatest public health concerns, such as
carcinogenicity and teratogenicity. Results in animal models were frequently
equivocal or inconsistent with human outcomes (Knight, 2011). Since then,
numerous additional reviews have yielded similar results. Baker et al. (2014),
for example, examined human neurological disease, which has been extensively studied in animal models, resulting in relatively few human treatments
(Cheeran et al., 2009; Vesterinen et al., 2010). Similarly, despite reports of the
efficacy of more than 1,000 treatments in animal models of multiple sclerosis
(MS), very few treatments have progressed to the marketplace (Vesterinen et
al., 2010). This usually indicates failures of efficacy or safety concerns in humans. And, despite the widespread use of animal models within stroke research, virtually no interventions described as effective in animal models have
proven similarly effective in human patients (Cheeran et al., 2009). There are
many other examples.
Several studies have sought to determine the maximal human clinical utility that may be achieved by animal models, by examining chimpanzee experiments, given that chimpanzees are our closest relatives (Knight, 2007);
by examining experiments approved by ethics committees on the basis of
explicit claims of likely human healthcare benefits (Lindl, Völkel and Kolar,
2005); or by examining highly-cited animal experiments published in leading
scientific journals (Hackam and Redelmeier, 2006). Hackam and Redelmeier,
for example, located 76 animal experiments, each of which had been cited
well over 500 times and published in one of the world’s seven top scientific
journals when ranked by journal impact factor. Hence, these experiments represented some of the most important and scientifically-interesting animal research published at the time. In only 28 cases (36.8%), animal results were
later replicated in humans. Most animal research is neither highly cited nor
published in world-leading journals, and successful translation to humans is
far lower.
3

Limitations of Animal Models

A variety of factors appear responsible for the poor rates of translation of outcomes from animal studies into human patients and consumers. These relate
both to the animal models themselves and to the ways in which they are used.
Fundamental biochemical differences between species may result in differences in absorption, distribution, metabolism, and elimination pathways or
rates, which may alter toxico- or pharmaco-kinetics (i.e., bodily distribution).
Toxico- and pharmaco-dynamics (mechanisms of action and biological effects)
may also be altered. Jointly these factors may contribute to differences in o rgan
systems affected and in the nature and magnitude of those effects (Hartung,
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2008; Knight, 2011). Further problems arise from the characteristics of the animals used. Biological variability and predictivity for humans are frequently
compromised by restriction to single rodent strains, young animals, and single
sexes, usually without concurrent human risk factors, such as common comorbidities, that can alter human responses to exogenous (externally-derived)
compounds (Hartung, 2008; Knight, 2011).
Additional problems arise from the ways in which the animals are used.
Many toxicity tests, for example, rely on maximum tolerated doses (above
which acute, toxicity-related effects preclude further dosing), and chronic
dosing. These factors maximize sensitivity to toxins, with the result that false
negative results rarely occur. However, these conditions can also overwhelm
the physiological defenses that are effective at environmentally realistic doses,
resulting in false positive outcomes. As a result, many compounds that would
not normally be considered toxic are falsely indicated as such by animal tests;
this substantially decreases the reliability and relevance of any positive result.
Additionally, important human routes of exposure (e.g., inhaled) may differ
from those tested in animals, requiring extrapolation between routes of exposure, as well as between species, introducing further uncertainty (Gold, Slone
and Ames, 1998; Hartung, 2008; Knight, 2011).
Furthermore, animals used in laboratories commonly experience a significant array of stressors. These include stresses incurred during handling,
restraint, and other routine laboratory procedures; and, in particular, the
stressful routes of dose administration common to toxicity tests. Orogastric
gavaging, for example, involves the insertion of a tube into the esophagus for
the forced administration of test compounds. Combined with environmental
stressors (e.g., due to limited space and environmental enrichment) and social
stressors (e.g., due to aggressive interactions between conspecifics), these represent a significant body of stressors. These stressors can alter physiological,
hormonal, and immune statuses and even cognitive capacities and behavioral
repertoires, in ways that are not always predictable (Balcombe, Barnard and
Sandusky, 2004; Balcombe, 2006; Baldwin and Bekoff, 2007). The results may
include alterations in the progression of diseases, in bodily responses to chemicals and test pharmaceuticals, and in a range of other scientific outcomes, such
as those dependent on accurate determination of physiological, b ehavioral, or
cognitive characteristics (for further discussion see Herrmann, 2019, Chapter 1;
Jayne and See, 2019, Chapter 21).
4

Methodological Quality of Animal Studies

As if these were not problem enough, a sizeable body of recent studies and
systematic reviews have confirmed the existence of significant methodological
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flaws, in most published animal experiments (e.g., Knight, 2008b). Indeed, to
date, no systematic reviews appear to have been published in which a majority of animal studies, assessed against appropriate objective criteria, were
found to have been of good methodological quality. In particular, a variety of
design features must be included within animal experiments to minimize the
potential for bias. Hooijmans et al. (2014) described 10 types of bias that have
the potential to influence animal experimental results, which they grouped
into selection bias, performance bias, detection bias, attrition bias, reporting
bias, and other sources of bias. Many of these flaws are highly prevalent within
animal studies.
Kilkenny et al. (2009) conducted one of the largest and most comprehensive
systematic surveys to date, assessing the experimental design, statistical analysis, and reporting of published animal experiments. 271 papers were examined,
which included 72 studies using mice, 86 using non-human primates, and 113
using rats. Most (99%; 269/271) of these papers were published between 2003
and 2005. They covered a wide variety of experimental fields, were published in
a comprehensive range of journals, and were funded by leading grant agencies
within the United Kingdom and the United States. However, only 59% of these
studies clearly stated the hypothesis or objective of the study and the number
and characteristics of the animals used. Details, such as animal strain, sex, age,
and weight, are all scientifically important and can potentially influence results
(Alfaro, 2005; GV-Solas, 1985; Obrink and Rehbinder, 2000). Nevertheless, in
many cases these details were omitted.
Knowledge of planned treatment (or lack thereof) is one of a number of factors that can unconsciously influence the assignment of animals to treatment
groups, for example, when researchers sympathetically select animals they
consider weaker, to be used as controls, rather than test animals. The introduction of such confounding factors (in this case, variable animal fitness), can
potentially bias results (in this case, selection bias has occurred). Accordingly,
randomized selection of animals for treatment groups is mandated, to ensure
that outcome differences are most likely due to treatment effects (Festing and
Altman, 2002; Festing et al., 2002). Haphazard selection does not give sufficient
certainty that results are truly random, so a systematic approach is necessary,
such as the use of a random number generator (Kilkenny et al., 2009). Nevertheless, despite its well-acknowledged importance, randomized allocation of
animals to test groups was reported in only 12% of these studies.
Another crucial feature of good experimental design concerns the assessment of outcomes. Where qualitative assessments occur, which involve assessor
judgements, it is similarly crucial that assessors do not know (are blinded to)
the treatment (or lack thereof) of the animals assessed, lest such knowledge
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subtly affect their judgement (Festing and Altman, 2002). Because, as Cochrane (1972) noted, “When humans have to make observations there is always
the possibility of bias,” even unintentional bias. Nevertheless, only 14% (5/35)
of all papers in the survey by Kilkenny et al. (2009) that reported qualitative
assessment of outcomes, also reported the use of blinding.
Many factors can affect experimental outcomes, so the incorporation of
measures to minimize sources of bias is crucial to ensuring the reliability of research results. And yet, 87% of papers, examined by Kilkenny and colleagues,
failed to report randomization during animal selection; and 86% failed to
report blinded assessment of outcomes. Additionally, only 70% of the publications that used statistical methods described their methods and presented
the results with a measure of error or variability. More recently, similar results
were found in an even larger study. Vogt et al. (2016) determined the prevalence
of seven basic measures against bias (i.e., allocation concealment, blinding,
randomization, sample size calculation, inclusion/exclusion criteria, primary
outcome variable, and statistical analysis plan), within 1,277 experimental applications approved by Swiss authorities in 2008, 2010, and 2012 and within
50 subsequent publications. Measures against bias were reported at very low
rates, both in experimental applications (2%–19%) and in subsequent publications (0%– 34%).
The importance of randomization and blinding when comparing two or
more experimental groups has been highlighted by reviews of animal research
in the field of emergency medicine, which have found that estimates of treatment efficacy were significantly reduced in studies that incorporated these
mechanisms to reduce risks of bias (Bebarta, Luyten and Heard, 2003; Macleod
et al., 2008). Similar results have been found in numerous other studies. In
fact, studies incorporating the fewest measures to minimize sources of bias
tended to report the greatest effect sizes (Crossley et al., 2008; Hirst et al., 2014;
Macleod et al., 2005; Rooke et al., 2011; Vesterinen et al., 2010). The widespread
failure to utilize mechanisms, such as randomization and blinding, appears
to result in false expectations of treatment efficacy and reported outcomes
in animals often fail to translate into humans. Similar results were reported
following a literature review by Holman, Head, Lanfear and Jennions (2015).
They found that blind protocols are uncommon in the life sciences, and that
non-blind studies tend to report more significant outcomes and higher effect
sizes. They noted that: “Observer bias and other ‘experimenter effects’ occur
when researchers’ expectations influence study outcome. These biases are
strongest when researchers expect a particular result, are measuring subjective
variables, and have an incentive to produce data that confirm predictions. To
minimize bias, it is good practice to work ‘blind,’ meaning that experimenters
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are unaware of the identity or treatment group of their subjects while conducting research” (p. 1).
Another common problem observed by Kilkenny et al. (2009) concerned
the transparency of reporting, and the robustness of statistical analysis. Almost 60% of surveyed publications were deficient in these areas. Most studies failed to provide sample sizes or adequate justifications of them. And yet,
studies that use too many animals waste animal lives. Conversely, the results
of underpowered studies (with insufficient numbers of experimental subjects) cannot be extrapolated to wider populations with sufficient certainty.
Accordingly, power analyses or other simple calculations are widely used
in human clinical trials to ensure enough subjects (but not more) are present to detect biologically important effects. Indisputably, the same principles
should apply to animal studies (Dell, Holleran and Ramakrishnan, 2002; Festing and A
 ltman, 2002).
Unfortunately, methodological flaws appear to be prevalent even within animal research conducted at highly-ranked universities and published in leading journals. After studying 814 randomly-selected studies reporting primary
research, 2,671 publications reporting drug efficacy in eight disease models,
and 4,859 publications from five UK institutions ranked highest across six units
of assessment in biomedical sciences, in the 2008 National Research Assessment Exercise, Macleod et al. (2015) reported that severe deficiencies of experimental design remain the norm. These deficiencies were prevalent in research
conducted at leading uk research universities, in research funded by leading
UK funding organizations, and in research reported in high-impact journals.
5

Evidence-based Research within Human Clinical Trials

The importance of sound experimental design, and, particularly, the necessity of incorporating factors designed to minimize bias risks have long been
recognized within the field of human research. The Consolidated Standards
of Reporting Trials (consort) Statement for randomized controlled human
clinical trials was one of the first guidelines developed to ensure the quality
of human-based research. It provides an evidence-based, minimum set of recommendations, including a checklist of 25 recommended items that should
be included when reporting randomized human trials (Moher, Schulz and
Altman, 2001; Schulz, Altman and Moher, 2010). Since then, more than 90
guidelines have been developed for reporting different types of health research
(see Altman et al., 2008; Simera et al., 2010; www.equator-network.org).
An increasing number of leading journals have, subsequently, requested that
their authors comply with the consort guidelines (Altman, 2005; Hopewell
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et al., 2008). Organizations commending the use of such guidelines include,
the Committee on Publication Ethics (n.d.); the Nuffield Council on Bioethics
(2005); the Council of Science Editors (2018); and the International Committee
of Medical Journal Editors (2015). Subsequent to the widespread endorsement
of such guidelines, studies have indicated that the quality and transparency of
reports on human clinical trials have improved (Plint et al., 2006; Kane, Wang
and Garrard, 2007).
6

Application to Animal Studies

More recently, multiple attempts have been made to introduce similar standards within animal studies. In 2009, Kilkenny and colleagues observed that
most biomedical journals provided little or no guidance about the reporting
of animal research, other than the requirement to report ethical review of the
proposed protocols. They noted the contrast between biomedical journals and
those within other several research areas, particularly medical research, in this
respect. Accordingly, in 2010, Kilkenny and colleagues proposed the Animal
Research: Reporting of In Vivo Experiments (arrive) guidelines. Prepared in
consultation with scientists, statisticians, journal editors, and research funders,
these guidelines comprise a checklist of 20 items, designed to provide minimum information on items, such as the number and specific characteristics
of animals used (including species, strain, sex, and genetic background); housing and husbandry conditions; and the experimental, statistical, and analytical
methods used. The latter points included measures to reduce bias, such as the
random allocation of animals to experimental groups, blinded assessment of
outcome measures, statistical justifications of sample sizes, reporting of animals excluded from analyses, exclusion criteria, and any investigator conflicts
of interest. The intention was that these items should be included within all
scientific publications reporting animal research, thereby allowing critical assessment of methods used and results obtained.
Hooijmans et al. (2010) similarly proposed a Gold Standard Publication Checklist (gspc), which includes 74 items designed to improve the quality of animal
studies and to fully integrate 3Rs “(replacement, reduction and refinement)”
methods and facilitate their incorporation within systematic reviews and metaanalyses. In 2014, Hooijmans and colleagues also proposed a Risk of Bias (RoB)
tool to assess methodological quality and risk of bias within animal studies. The
tool is based on the similar Cochrane RoB tool (Higgins et al., 2011), which was
adjusted for particular aspects of bias that play a role in animal studies.
Other authors have proposed similar guidelines and checklists for the conduct and reporting of animal research. In 2009, Osborne and colleagues from
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the Royal Society for the Prevention of Cruelty to Animals (UK) proposed a
12-point assessment scheme for scoring biomedical journals’ policies on animal welfare and the 3Rs. And in 2015, Martins and Franco proposed their
Excellence in Editorial Mandatory Policies for Animal Research (exemplar)
scale, comprising four categories: regulatory compliance, quality of research
and reporting of results, animal welfare and ethics, and criteria for the exclusion of papers.
7

Poor Compliance of Animal Studies

Such guidelines provide indisputable benefits in ensuring the reporting of
methodological quality, reliability of results, and incorporation of the 3R
principles of animal research. The arrive guidelines of Kilkenny et al. (2010)
have been published or endorsed by more than 1,000 research journals, including those published by the N
 ature Publishing Group, PLoS, and BioMed Central (Reichlin, Vogt and Würbel, 2016). They have been similarly endorsed by
major UK funding agencies (including the Wellcome Trust, the Biotechnology
and Biological Sciences Research Council, and the Medical Research Council);
and they also form part of the US National Research Council Institute for Laboratory Animal Research guidelines (Baker et al., 2014). And yet, despite such
widespread endorsement, a number of studies have demonstrated that compliance with such guidelines remains poor.
Noting that, “Despite reports of over 1,000 treatments effective in animal
models of multiple sclerosis (MS), very few treatments have so far made it
to the marketplace following initial development in disease-related animal
models (Vesterinen et al., 2010),” Baker et al. (2014) investigated the general
adequacy of reporting within animal studies of MS. They uncovered significant inadequacies within the reporting of experimental design, including the
selection of appropriate statistical analyses and the application of key points
in the arrive guidelines. They observed that the arrive guidelines are not
being implemented by authors, reviewers, and journal editors (Baker and
Amor, 2012; Landis et al., 2012; Schwarz, Iglhaut and Becker, 2012).
Despite their very widespread publication and endorsement, lack of awareness of such guidelines appears to remain a major problem. After surveying all registered in vivo researchers in Switzerland recently, Reichlin et al.
(2016) reported that among 302 self-selected participants, 56.3% did not
know of the arrive Guidelines. A total of 1,891 researchers were surveyed,
but only 302 (16%) returned fully-completed questionnaires and, hence,
were not excluded. Even among those whose latest paper was published in
a journal that had endorsed the arrive guidelines, 51% had never heard
of them.
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The failure of biomedical journals to insist on compliance with quality
control standards is partly to blame. After surveying 236 biomedical journals’
policies on animal research, Osborne et al. (2009) found no mention of animal
use, within author guidelines or elsewhere, in 35% of journals studied. In 18%
of the journals, animals were mentioned, but no perceptible guidelines were
provided; and most of the remaining journals scored poorly, with 37% scoring three or fewer points out of 12 equally weighted items within their quality
checklist. Martins and Franco (2015) examined 170 journals that publish studies on animal models of three human diseases, namely Amyotrophic Lateral
Sclerosis (als, also known as Motor Neuron Disease); Type-1 Diabetes; and
Tuberculosis. Their results were broadly similar to the results of a survey by
Osborne et al.’s. (2009), when assessing studies using their exemplar scale.
They noted that, “little progress found regarding in-house policies on the ethical treatment of animals is worrisome” (p. 325).
8

Improving Study Quality

A range of measures are strongly warranted to increase the implementation of
the 3R principles, the methodological quality of animal research, and the reliability of results and to overcome some of the barriers that currently prevent
reliable extrapolation to human outcomes.
Compliance with each of the 3Rs and the arrive guidelines and other best
practice standards, during the design, conduct, and reporting of experiments,
must become mandatory. Such standards should cover animal sourcing, housing, environmental enrichment, socialization opportunities, appropriate use
of anesthetics and analgesics, handling, non-invasive endpoints, and a range
of measures designed to minimize sources of bias and to ensure methodological quality. Compliance with such standards should be a necessary condition
for securing research funding and ethical approval; licensing of researchers,
facilities, and experimental protocols; and publication of subsequent results.
Compliance would also facilitate subsequent systematic reviews.
Where journal space constraints limit the description of methodological
details, these should be included in supplementary online databases, which
are now widely available (Kilkenny et al., 2009). This would also facilitate the
transfer of alternative technologies, such as the development of new alternative methods, between institutions (Gruber and Hartung, 2004).
To enable animal researchers and technicians to meet the necessary standards, training and continuing professional development in 3R methodologies
and the design, conduct, and reporting of animal research should be compulsory. The existing lack of focus on replacement methods (in favor of refinement
methods) must be addressed.
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The adoption of measures, such as these, would increase the reliability of research results and would facilitate their use within systematic reviews. Prior to
designing any new animal study, researchers should conduct a systematic review
to collate, appraise, and synthesize all existing, good-quality evidence r elating to
their research questions. Such systematic reviews should be similarly required
by grant agencies, ethical review committees, other animal-experiment licensing bodies, and journals. Systematic reviews are studies in and of themselves. In
recognition of their intrinsic value, and their necessity for informing further research, they should also be readily funded by grant agencies.
To ensure that all such evidence is publicly available, greater efforts must
also be made by researchers and editors to publish negative results. Studies
that fail to show a treatment effect are often considered less interesting and
are, consequently, less likely to be published. The subsequent exclusion of such
results from systematic reviews leads to over-estimations of treatment efficacy
and partly explains the widespread failures in humans of treatments apparently efficacious in animals.
Within the field of human studies, clinical trial registers allow researchers
to learn about existing and prior clinical trials, including those with negative
outcomes, before results are formally published. A similar international initiative to register animal studies and their results is warranted (Hooijmans
et al., 2014).
Many of these measures will require cooperation and coordination between
researchers, regulators, licensing bodies, ethical review committees, funding bodies, journals, and authors. And of course, the necessary willingness,
among all parties, to change. If these measures were to be successfully implemented throughout the broad field of animal research, then we may be able
to predict treatment effects accurately within the animal species under study.
However, interspecies differences will remain in absorption, distribution, metabolism, and elimination pathways or rates, resulting in differing toxico- or
pharmaco-kinetics and dynamics and, subsequently, differences in the organ
systems affected and in the nature and magnitude of these effects. Such factors, which reflect the intrinsic complexity of living organisms, will continue to
pose b arriers to extrapolation to humans that will remain insurmountable, in
many cases.
9

Impacts on Laboratory Animals

Human patients are far from the only victims of poorly conducted, poorly
predictive, animal research. A wide variety of stressors have the potential to
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cause significant stress, fear, and possibly distress in laboratory animals. These
stressors may be associated with the capture of wild-sourced species, such
as primates, to supply laboratories or breeding centers; with transportation,
which may be prolonged for some animals; with laboratory housing and environments; and with both routine and invasive laboratory procedures (see
Knight, 2011). An invasive procedure is an intervention that interferes with bodily integrity through puncture, incision, or insertion of an instrument or foreign
material, as in surgical and some experimental procedures (Knight, 2011).
A large minority of all procedures are markedly invasive. These include procedures resulting in death (whether or not the animals are conscious); surgical
procedures (excluding very minor operative procedures); major physiological
challenges; and the production of genetically-modified animals. Few regions
report procedural invasiveness, but Canada does. From 1996–2008 inclusively,
the proportion of markedly invasive procedures reported in Canada ranged
between approximately 29%–44% (Canadian Council on Animal Care, 2009).
These procedures were defined by the Canadian Council on Animal Care
(2009) as resulting in moderate to severe stress or discomfort (Category D); or
in severe pain near, at, or above the pain tolerance threshold of unanesthetized
conscious animals (Category E) compared to procedures resulting in little or
no discomfort or stress (Category B) or minor stress or pain of short duration
(Category C).
A sizeable majority of all procedures utilize no anesthetics of any kind. Few
regions report anesthetic usage, but Britain does. During two recent decades
(1998–2009), the proportion of procedures conducted in the UK without anesthesia fluctuated between approximately 59%–69% (Home Office, 2010). For
example, in 2009, at the end of this period, 66.7% of cases did not utilize any
form of anesthesia. General anesthesia was provided throughout or at the end
of terminal procedures in 9.5% of cases. In 17.1% of cases, general anesthesia
with recovery was provided, and in 6.7% of cases, local anesthesia (Home
Office, 2010).
To assess animal impacts further, it is helpful to know the frequency of analgesic (pain-killer) use, and the level of correlation between markedly invasive
procedures and anesthetic or analgesic use (See Herrmann and Flecknell (2018)
for a review of original animal research proposals). Painful or invasive procedures warrant anesthesia and/or analgesia. Animal welfare is adversely affected when animals undergoing such procedures are denied these; or c onversely,
when they are provided without sufficient need (due to their p
 otential side
effects), although this is rare in practice. It would also be helpful to study the
prevalence of environmental enrichment and socialization opportunities. Unfortunately, such information remains largely unreported.
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Conclusions

Animal research is a mechanism by which we seek to increase our understanding of the biological world. The major useful applications of this knowledge lie
in the development of new therapies for combatting human diseases and in
predicting the human toxicity of chemicals used for a wide range of purposes.
As we have seen, however, the actual efficacy of animal research for these purposes is very low. This is due to a range of causes, some of which are, at least
theoretically, amenable to change and some of which are not.
When formulating social policy pertaining to animal research, the social
benefits realized are only part of the equation. The other major part that must
be considered concerns the resources consumed by this research. The very
substantial financial and scientific resources consumed by animal research
are consequently unavailable to other fields, some of which, such as preventative healthcare or human clinical research, may well be expected to produce
greater gains for public health. And as we have seen, the impacts on animals
are also severe. 127 million living non-human vertebrates were used worldwide
in 2005, the most recent year for which an evidence-based global estimate
was available. Based on figures from countries, such as Canada and the UK,
where these are published, a large minority of all procedures are markedly
invasive; and a sizeable majority utilize (or at least report) no anesthetics of
any kind.
The core ethical principle underpinning modern animal experimentation
regulation and policy is that the likely benefits of such research must outweigh its expected costs. This utilitarian harm-benefit analysis underpins all
fundamental regulation governing animal experimentation. For example, European Directive 2010/63/EU on the protection of animals used for scientific
purposes, which directs such animal use in all EU Member States, asserts that
it is “essential, both on moral and scientific grounds, to ensure that each use
of an animal is carefully evaluated as to the scientific or educational validity,
usefulness, and relevance of the expected result of that use. The likely harm to
the animal should be balanced against the expected benefits of the project”
(European Parliament, 2010, p. 37).
When considering harms and benefits overall, one cannot reasonably conclude that the benefits accrued for human patients or consumers, or those motivated by scientific curiosity or profit, exceed the harms incurred by animals
subjected to scientific procedures. On the contrary, evidence indicates that actual human benefit is rarely, if ever, sufficient to justify such harms. And those
harms are not limited to the many millions of animals used. Others potentially affected include patients and consumers. The social and ethical implications are profound, when consumers suffer serious toxic reactions to products
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assessed as safe in animal studies, or if patients with serious conditions are
denied effective clinical interventions, partly because potentially more efficacious research fields are under-resourced (Knight, 2011).
A paradigm change in scientific animal use is clearly warranted. Instead of
uncritically assuming the benefits of animal research, we must subject it to
much more rigorous and critical evaluation. Where animal research continues
to persist, a broad range of measures must be implemented to improve substantially its methodological quality and compliance with the 3Rs and to maximize the reliability of subsequent results (Knight, 2011). When such research
fails to meet the harm-benefit standards expected by society, which underpin legislative instruments, such as Directive 2010/63/EU, then such research
should cease; and the resources consumed by it directed into more promising
and justifiable fields of research and healthcare.
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